|1.||Ruzdijić, Sabera: 3 articles (04/2009 - 08/2002)|
|2.||Rakić, Ljubisav: 2 articles (01/2013 - 01/2006)|
|3.||Rakić, Ljubisa: 2 articles (04/2009 - 08/2002)|
|4.||Pesić, Milica: 2 articles (04/2009 - 01/2006)|
|5.||Kanazir, Selma: 2 articles (01/2006 - 08/2002)|
|6.||Ruždijić, Sabera: 1 article (01/2013)|
|7.||Pešić, Milica: 1 article (01/2013)|
|8.||Dačević, Mirjana: 1 article (01/2013)|
|9.||Podolski-Renić, Ana: 1 article (01/2013)|
|10.||Stanković, Tijana: 1 article (01/2013)|
05/01/1990 - "Sulfinosine penetrated the central nervous system more readily than did 6TGR and, when given repeatedly, was much more effective in the treatment of L1210 leukemia, being curative for some mice. "
01/01/1990 - "Sulfenosine (8b) at 22 mg/kg per day X 1 showed a T/C of 170, whereas sulfinosine (9b) at 173 mg/kg per day X 1 showed a T/C of 167 against L1210 leukemia. "
01/01/2006 - "The combination of sulfinosine and 8-Cl-cAMP induces synergistic cell growth inhibition of the human neuroblastoma cell line in vitro."
01/01/2006 - "To identify purine analogs that could be effective in treating neuroblastomas, we tested the anticancer properties of sulfinosine, 8-Cl-cAMP and 8-Cl-adenosine in the SK-N-SH cell line. "
|3.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
04/01/2009 - "A resistant non-small cell lung carcinoma cell line-NSCLC (NCI-H460/R) was established in order to investigate the potential of sulfinosine (SF) to overcome multidrug resistance (MDR). "
04/01/2009 - "Sulfinosine enhances doxorubicin efficacy through synergism and by reversing multidrug resistance in the human non-small cell lung carcinoma cell line (NCI-H460/R)."
07/01/2008 - "Our results show that sulfinosine and curcumin overcome MDR in non-small cell lung carcinoma cell line (NSCLC), especially in combination despite the presence of a mutated p53 gene."
07/01/2008 - "We tested the potential of sulfinosine and curcumin, alone and in combination, for modulating MDR in the human resistant, non-small cell lung carcinoma cell line (NCI-H460/R). "
08/01/2002 - "In the present study, we used the novel purine ribunocleoside sulfinosine and evaluated its antiproliferative and apoptotic outcome on the non-small cell lung carcinoma cell line (NSCLC) and the small cell lung carcinoma cell line (SCLC). "
|4.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
|5.||Lung Neoplasms (Lung Cancer)
|2.||8-chloro-cyclic adenosine monophosphate